Von Hippel-Lindau Disease Epidemiology and Clinical Significance

Disease Incidence and Prevalence

The American College of Medical Genetics and Genomics acknowledges that Von Hippel-Lindau disease is classified as a rare disease, with an estimated incidence of approximately 1 in 36,000 live births and a prevalence of 1 in 46,900 individuals 1

The National Comprehensive Cancer Network notes that lifetime penetrance approaches 100% by age 75, meaning virtually all mutation carriers will develop manifestations if they live long enough 1, 2
Approximately 80% of cases are inherited from an affected parent, while 20% arise from de novo mutations, which means absence of family history does not exclude the diagnosis, as reported by the American Society of Clinical Oncology 3, 4, 1

Historically, median life expectancy was only 49 years, though recent data suggests improvement to 60-67 years for those born in 2000 due to better surveillance and treatment, according to the American Academy of Ophthalmology 5
VHL-related tumors were the cause of death in 79% of affected individuals in historical cohorts, with renal cell carcinoma, CNS hemangioblastomas, and pancreatic neuroendocrine tumors being the primary causes of mortality, as stated by the National Cancer Institute 5, 3
Vision loss occurs in approximately 20% of patients from retinal hemangioblastomas if not detected and treated early, highlighting the importance of regular screening, as recommended by the American Academy of Ophthalmology 1